课题基金 / 基金详情

次级淋巴器官微环境对MDSC及相关细胞的调控及其在诱导异基因造血干细胞移植免疫耐受中的作用

批准号:
81970160
项目类别:
面上项目
资助金额:
55.0 万元
负责人:
任汉云
依托单位:
学科分类:
造血干细胞移植与并发症
结题年份:
2023
批准年份:
2019
项目状态:
已结题
项目参与者:
任汉云

项目摘要

结项摘要

项目成果

任汉云的其他基金

相似基金

相关文献

中文摘要
研究证据表明,次级淋巴器官(SLO)是诱导免疫耐受发生的重要场所,这种现象可发生于肿瘤和异体器官移植诱导的免疫耐受,其MDSC及其相关细胞可能起重要作用。该研究拟确定SLO中微环境FRC为诱导免疫耐受的中心环节,不仅直接抑制T细胞增殖和活化,也可促使MDSC及相关细胞生成发挥对T细胞活化的抑制作用。应用已建立的GVHD模型和阻断T细胞趋化使T细胞滞留于SLO而预防GVHD模型证明T细胞在SLO中的活化程度低于GVHD靶器官中T细胞活化程度,靶向阻断趋化因子受体使T细胞滞留于SLO可进一步抑制T细胞活化,这种免疫抑制作用与MDSC生成有关。本研究拟通过对比分析SLO和GVHD靶器官免疫细胞和免疫相关分子的差异,初步阐明SLO诱导免疫耐受机制。该研究的意义在于确定在allo-HSCT条件下SLO是免疫耐受诱导器官,FRC及其诱导扩增的MDSC及其相应细胞是诱导免疫耐受的中心环节。
英文摘要
More and more evidences demonstrated that secondary lymphatic organs (SLOs) are important sites for immune tolerance induction. This phenomenon not only take place in tumor-induced but also in allograft-induced immune tolerance.MDSC and its related antigen-presenting cells may be important in this process. In this study, we will probe the microenvironment in SLOs, especially fibroblastic reticular cells (FRC),play a central role in immune tolerance. It not only directly inhibit proliferation and activation of conventional T cells, but it may promote the expension of MDSC and its related cells in SLOs. Also, FRC might promote the expression of checkpoint molecular PD-L1/2 and other immune inhibitory moleculars on antigen-presenting cells which may induce T cell tolerance. We will try to conform that T cells in SLOs is less activated than that in GVHD organ such as liver through a murine GVHD model. Our previous studies showed that blockade of chemokine receptors could lead to retention of donor-derived T cells to SLOs and attenuate murine acute GVHD. We try to use established murine GVHD model and T cell SLO retention model by blockage of chemokine receptors to illuminate the cellular and molecular mechanisms underlying SLO-induced immune tolerance through comparative study of immune cells and immune-related molecular in SLOs and GVHD-targeted organs. Though these series studies, we might confirm that SLOs are immune tolerance-induced organs under the condition of allo-HSCT,FRC as well as MDSC and its related cells expended from myeloid progenitor cells in graft may play a central role in inducing immune tolerance.
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
DOI: 10.1155/2021/9958745
发表时间: 2021
期刊: BioMed research international
影响因子: --
作者: [Yu Z, Qin C, Cao M, He X, Ren H, Liu H]
通讯作者: Liu H
Lymph Node Fibroblastic Reticular Cells Attenuate Immune Responses Through Induction of Tolerogenic Macrophages at Early Stage of Transplantation
淋巴结成纤维细胞网状细胞通过在移植早期诱导耐受性巨噬细胞来减弱免疫反应
DOI: 10.1097/tp.0000000000004245
发表时间: 2022
期刊: Transplantation
影响因子: 6.2
作者: [Beichen Liu, Huihui Liu, Siwei Liu, Chenchen Qin, Xiaoya He, Zhengyang Song, Yujun Dong, H. Ren]
通讯作者: H. Ren
DOI: 10.1186/s13287-021-02459-7
发表时间: 2021-07-02
期刊: Stem cell research & therapy
影响因子: 7.5
作者: [Cao M, Liu H, Dong Y, Liu W, Yu Z, Wang Q, Wang Q, Liang Z, Li Y, Ren H]
通讯作者: Ren H
DOI: 10.3389/fimmu.2022.780708
发表时间: 2022
期刊: Frontiers in immunology
影响因子: 7.3
作者: [Wang QY, Liu HH, Dong YJ, Liang ZY, Yin Y, Liu W, Wang QY, Wang Q, Sun YH, Xu WL, Han N, Li Y, Ren HY]
通讯作者: Ren HY
促T细胞CCR7表达诱导异基因造血干细胞移植后免疫耐受的机制研究
  • 批准号:
    81570160
  • 项目类别:
    面上项目
  • 资助金额:
    60.0万元
  • 批准年份:
    2015
  • 负责人:
    任汉云
  • 依托单位:
靶向抑制CCR5功能及表达预防急性GVHD免疫学机制的研究
  • 批准号:
    81370667
  • 项目类别:
    面上项目
  • 资助金额:
    75.0万元
  • 批准年份:
    2013
  • 负责人:
    任汉云
  • 依托单位:
间充质干细胞对异基因T细胞体内趋化影响机制的研究
  • 批准号:
    81070448
  • 项目类别:
    面上项目
  • 资助金额:
    34.0万元
  • 批准年份:
    2010
  • 负责人:
    任汉云
  • 依托单位:
间充质干细胞改变异基因T淋巴细胞趋化特性及其机制的研究
  • 批准号:
    30940030
  • 项目类别:
    专项基金项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2009
  • 负责人:
    任汉云
  • 依托单位:
国内基金
海外基金